Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short DAPT followed by prasugrel monotherapy versus standard DAPT in STEMI, with OCT-guided versus angiography-guided complete revascularization
NL-OMON54076Recruiting
- Sponsor
- Research Cardiologen Rotterdam Zuid
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of prasugrel and aspirin in acute ST-segment elevation myocardial infarction (STEMI) (4 arms), sponsored by Research Cardiologen Rotterdam Zuid. Primary endpoints: Net adverse clinical events at 11 months post DAPT randomization and Post-procedural minimal stent area. Started Jul 2022; status: recruiting.
02
Drugs
prasugrelaspirin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NL-OMON54076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54076.